Capital Berg

Keeps People Up-To-Date

Monday, April 19, 2021
Log in
  • United States
  • Business
  • Health
  • Science
  • Technology
  • About CapitalBerg
    • Analysts & Contributors
    • Advertising
    • Contact US
    • Privacy Policy GDPR
    • Terms of Use

Pages

  • About CapitalBerg
  • Advertising
  • Analysts & Contributors
  • Contact US
  • Investor Relations
  • Privacy Policy GDPR
  • SEC Disclosure
  • Terms of Use

Recent Posts

  • Tennessee Rapist Breaks into Woman’s House Three Times the Same Night to Assault Her June 29, 2018
  • Mentally Ill Man Arrested After Breaking into Retirement Home to Grope a Woman’s Chest June 28, 2018
  • “Syndrome” Author Blake Leibel Sentenced to Life in Prison for the Murder and Torture of Girlfriend June 27, 2018
  • Michigan Dad to Be Sentenced in the Beating Death of 3-Year-Old Infant June 26, 2018
  • Ohio Patrolman Booted from Police After Pulling Over His Daughter and Boyfriend June 26, 2018
  • Utah Mayor Shares Heartwarming Letter of Man Apologizing for Stealing a Stop Sign 75 Years Ago June 25, 2018
  • Mississippi Man Beheaded Mother After A Spat over Credit Cards June 25, 2018

Sarepta Still Has a Chance for FDA Approval

July 17, 2016 By Waleed Javed

muscular dystrophy

              Sarepta may have a chance to see its muscular dystrophy drug approved by FDA.

Sarepta Therapeutics had to deal with a market share drop after the Food and Drug Administration rejected Raxone, the rival Duchenne muscular atrophy drug.

Experts say that Sarepta’s chances could be dimmed by the recent rejection.

Duchenne muscular atrophy is a rare genetic disorder that causes a gradual deterioration of muscles and later impacts all body functions. It only affects little boys, and it results in death at the age of 20 or 30.

One in 3,500 boys gets the disease, and most of them are losing all motor functions until they reach adulthood. The condition has no cure.

FDA Suite of Rejections

The families and patient advocacy groups put a lot of pressure on FDA to approve the new drugs. However, the agency did not find hard evidence of clinical benefits in the medicines that were submitted for approval so far.

FDA recently rejected Kyndrisa, developed by BioMarin Pharmaceuticals, Ataluren, created by PTC Therapeutics, and Raxone from Santhera. All the three drugs presented a low rate of positive results.

Raxone, the latest drug to be rejected, had forwarded a Phase 3 study to FDA. The agency requested a new trial, which will take another three years. Santhera will start as soon as possible. However, the results will come only in 2019.

Eteplisen, the experimental drug developed by Sarepta, had the same difficult road of approval. Earlier this year, FDA rejected a small trial testing based on 12 DMD patients. The results were a 0.9% increase in dystrophin production. FDA requested muscle biopsy data for patients that are on the 48th week of treatment.

Sarepta Still Has A Chance

Raxone’s rejection in Phase 3 of the trial could be a sign that the FDA will not readily accept Eteplisen either.

Raxone was created to stimulate mitochondria, which would improve lung function for Duchenne muscular atrophy patients.

Eteplisen uses another strategy. It tries to act directly on the dystrophin production. Over the course of four years, the drug showed improvements in patients’ history data.

As a consequence, analysts recommend Sarepta shares as the Raxone’s rejection will probably have no impact on Eteplisen as the drug works entirely different.

Eteplisen will probably work only on 1,300-1,900 patients in the state. Roxanne will have a larger spectrum of applications, including Leber’s hereditary optic neuropathy, Freidrich’s ataxia, or Alzheimer.

The political pressure, patient advocacy and the positive results on the disease may all act in the favor of Sarepta. Other market analysts think that, in fact, FDA will continue to reject all DMD medicines until they have their high standards attained.

Image Source: Wikipedia

  • About the Author

About Waleed Javed

Filed Under: Health Tagged With: BioMarin Pharmaceuticals, Duchenne muscular atrophy, Eteplisen, FDA approval, Muscular Dystrophy, PTC Therapeutics, Santhera, Sarepta, Sarepta Still Fights for FDA Approval

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 44 other subscribers

Recent Articles

sleep

Tennessee Rapist Breaks into Woman’s House Three Times the Same Night to Assault Her

June 29, 2018 By Denise Ehrlich Leave a Comment

police lights

Mentally Ill Man Arrested After Breaking into Retirement Home to Grope a Woman’s Chest

June 28, 2018 By Waleed Javed Leave a Comment

gavel

“Syndrome” Author Blake Leibel Sentenced to Life in Prison for the Murder and Torture of Girlfriend

June 27, 2018 By Andreas Petersen Leave a Comment

Woods

Michigan Dad to Be Sentenced in the Beating Death of 3-Year-Old Infant

June 26, 2018 By Marlene R. Litten Leave a Comment

patrol cruiser

Ohio Patrolman Booted from Police After Pulling Over His Daughter and Boyfriend

June 26, 2018 By Waleed Javed Leave a Comment

stop sign

Utah Mayor Shares Heartwarming Letter of Man Apologizing for Stealing a Stop Sign 75 Years Ago

June 25, 2018 By June Harris Leave a Comment

Butter knives

Mississippi Man Beheaded Mother After A Spat over Credit Cards

June 25, 2018 By Carol Harper Leave a Comment

XXXTentacion mugshot

Florida Authorities Arrested Suspect in Connection with Shooting of XXXTentacion

June 22, 2018 By Waleed Javed Leave a Comment

sunset over beach

Dallas Mother Accused of Beating Four-Year-Old and Dumping Body Into the Water

June 21, 2018 By Denise Ehrlich Leave a Comment

chicken Alfredo

Ohio Man Sentenced for Trying to Seduce Teenage Boy with Naked Pictures and Chicken Alfredo

June 20, 2018 By Marlene R. Litten Leave a Comment

bedroom

South Carolina Teen and Mates End Up In Slammer for Raping a Teenage Girl

June 19, 2018 By Waleed Javed Leave a Comment

cyberstalkin

California Man Arrested for Stalking Ex-Girlfriend, Hacking Her Online Accounts

June 19, 2018 By June Harris Leave a Comment

hammer

Naked Patient Sneaks out of Emergency Room to Bash Homeowner’s Head with Hammer

June 18, 2018 By Carol Harper Leave a Comment

screwdriver

Middle School Student Attacks Teacher During Class with Screwdriver

June 18, 2018 By Andreas Petersen Leave a Comment

Related Articles

  • Virtual reality

    French Hospital Employs Virtual Reality to Curb Patient’s Pain

    Jun 13, 2018
  • surgery

    Danish Doctors Baffled by Patient Remaining Awake after During Cardiac Arrest

    Jun 5, 2018
  • medical implant

    MIT Think-Thanks Designed the World’s First Wireless Medical Implant

    Jun 5, 2018
  • human eye

    Australian Woman Nearly Goes Blind Because She Forgot to Remove her Makeup

    Jun 4, 2018
  • Snorting Condoms Challenge.

    Snorting Condoms Challenge on the Rise, Health Officials Declared

    Apr 2, 2018
  • Florida Woman Mommy Belly

    Florida Woman Mistook Labor Pains for Food Poisoning

    Mar 30, 2018
  • Surgical sponges.

    Japanese Surgeons Discovered Surgical Sponges in Women’s Abdomen

    Feb 23, 2018
  • British accent cards.

    Texas Woman Goes to Sleep, Wakes Up with British Accent

    Feb 13, 2018
  • Woodpeckers and CTE

    Woodpeckers Not Invulnerable to Brain Damage, New Study Suggests

    Feb 6, 2018
  • Gummy beart

    New Mexico School Students Intoxicated After Eating Marijuana-Laced Gummy Bears

    Jan 24, 2018

Categories

  • Business
  • Deals
  • Health
  • Science
  • Technology
  • United States
  • World

Copyright © 2021 capitalberg.com

About · Privacy Policy · Terms of Use · Contact